Test Price
2,800 AED✅ Home Collection Available
KIT Gene Mutation Analysis for Acute Myeloid Leukemia – Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary: This NGS-based molecular test detects activating mutations in the KIT gene, providing critical prognostic and therapeutic guidance for core-binding factor acute myeloid leukemia (CBF-AML). Results enable personalized treatment with tyrosine kinase inhibitors under DHA-licensed supervision.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified laboratory processing.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection, available daily 8 AM – 11 PM.
- Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by a DHA-licensed medical geneticist.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
KIT gene mutation analysis using Next‑Generation Sequencing (NGS) is the gold standard for detecting activating mutations in core‑binding factor acute myeloid leukemia (CBF‑AML). This test directly impacts risk stratification and guides therapy with tyrosine kinase inhibitors (TKIs) such as midostaurin, offering actionable data for personalized treatment planning.
| Feature | Our Test (Premium UAE) | Closest Alternative |
|---|---|---|
| Methodology | NGS (Illumina® platform, >1000× coverage) | Sanger sequencing (single‑gene analysis) |
| Analytical Sensitivity | Detects variants at 1% variant allele frequency (VAF) | Limited to ~20% VAF |
| Turnaround Time | 3 to 4 Weeks | 6–8 Weeks |
| Interpretation | Clinically annotated report with DHA‑licensed medical geneticist review | Raw data only, often without clinical correlation |
| Price | 2800 AED | 3500 AED |
All methods are calibrated against certified reference materials. NGS is the recommended first‑tier test for AML‑associated KIT mutations.
Physician Insight & Safety Protocols
“KIT mutation testing provides critical prognostic information, but it must be interpreted in the context of cytogenetics, other molecular markers, and clinical presentation. No single test replaces a comprehensive diagnostic workup. I strongly advise patients to review all results with their treating hematologist before making any treatment decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Pre-Procedure Safety Advisory
Safety & Consent: This test involves venous blood collection. All procedures comply with Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring informed consent and patient safety. Patients with active chemotherapy and platelet count < 50,000/µL should defer collection until counts recover. Grossly haemolyzed or contaminated samples require recollection.
Pre-Test Requirement: A clinical history and genetic counselling session to construct a pedigree chart of family members affected with KIT‑related leukemia are strongly recommended before sample collection.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients on active chemotherapy with platelet count < 50,000/µL should defer blood collection until counts recover; grossly haemolyzed or contaminated samples require recollection.
- Seek Emergency Care if: After the procedure you experience unexplained bruising, new‑onset fever >38°C, or severe fatigue and pallor — these may indicate a medical emergency unrelated to the draw.
Patient FAQ & Clinical Guidance
1. What is the KIT gene mutation test for acute myeloid leukemia?
Snippet: This NGS test detects KIT gene mutations that alter AML risk stratification and tyrosine kinase inhibitor response, achieving 99.9% accuracy.
The test analyzes DNA from whole blood, extracted DNA, or a single drop of blood on an FTA card using high‑depth next‑generation sequencing. It identifies both known and novel variants in the KIT gene, which are commonly found in core‑binding factor AML. The results empower your oncology team to tailor treatment with targeted therapies like midostaurin, dasatinib, or clinical trial eligibility.
2. How is the sample collected for this genetic test?
Snippet: A venous blood sample or one drop of blood on an FTA card is collected by a licensed phlebotomist during cold‑chain home collection.
We offer a secure, hospital‑grade home collection service with ISO‑certified cold‑chain logistics. A DHA‑licensed phlebotomist will arrive at your doorstep between 8 AM and 11 PM, collect the required sample (blood or preserved DNA card), and immediately transport it in a temperature‑controlled container to our central lab. This ensures zero degradation and the highest molecular yield.
3. How long does it take to receive results?
Snippet: Results are delivered within 3 to 4 weeks via a secure patient portal with telephonic clinical guidance from our expert team.
After the sample reaches our lab, NGS library preparation, sequencing, bioinformatics analysis, and DHA‑approved clinical interpretation are completed in 3 to 4 weeks. You will receive a detailed report in both English and Arabic (upon request) through a HIPAA‑equivalent encrypted portal. A 15‑minute telephonic consultation with a clinical geneticist or oncologist is included to explain the findings and answer any questions.
UAE Regulatory & Data Privacy Adherence
UAE Regulatory Compliance: This genetic test strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for genetic data privacy and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All procedures are conducted under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | KIT Gene Mutation Analysis for Acute Myeloid Leukemia (Genetic Test) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral whole blood, extracted DNA, or FTA card (dried blood spot) |
| Methodology Used | Next‑Generation Sequencing (NGS), Illumina® platform, >1000× coverage |
| ICD-10-CM Code | C92.8, Z15.09, Z80.6 |
| LOINC Code | 21634-8 – KIT gene mutation analysis in Blood or Tissue by Sequencing |
| DHA Facility License & Address | DNA Labs UAE | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians